阅读说明：本技术 用于预防、矫正、变换和修改面部美学且关于其而咨询患者的方法和系统 (Method and system for preventing, correcting, transforming and modifying facial aesthetics and consulting patients about the same ) 是由 毛里西奥·迪·马伊奥·杜明高斯 于 2018-02-10 设计创作，主要内容包括：本文中提供了MD Codes、MD DYNA Codes、MD ASA和Next Human系统,以及使用它们来诊断并治疗美学症状或疾病的方法。(Provided herein are MD Codes, MD DYNA Codes, MD ASA and Next Human systems, and methods of using them to diagnose and treat aesthetic conditions or diseases.)

1. A method of treating a subject having a disorder or disease, comprising:

providing a subject having a disorder or disease;

selecting at least one or more MD Codes to treat the condition or disease, wherein the MD Codes indicate an injection site on the face or neck of the subject; and is

A therapeutically effective amount of the pharmaceutical composition is injected at the injection side.

2. A method of providing a consultation for a subject, comprising:

identifying a disorder or disease in the subject;

identifying at least one or more MD Codes useful for treating the disorder or disease; wherein the MD Codes indicate injection sites on the face or neck of the subject;

generating a treatment plan to inject a therapeutically effective amount of a pharmaceutical composition at the injection side identified by the MD Codes; and is

The treatment plan is optionally visualized on a graphical display.

3. The method of any one of claims 1 or 2, wherein the pharmaceutical ingredient is botulinum toxin type a.

4. The method according to any one of claims 1 or 2, wherein the pharmaceutical ingredient is a long-chain Hyaluronic Acid (HA) product.

5. The method of any one of claims 1 or 2, wherein the pharmaceutical composition comprises HA.

6. The method according to any one of claims 1 or 2, wherein the pharmaceutical ingredient is deoxycholic acid.

7. The method according to any of claims 1 or 2, wherein the MD Codes are substantially as set forth in any of figures 1-7 described in the MDCodes section.

8. The method according to any of claims 1 or 2, wherein the MD Codes are set forth in any of fig. 1-7 described in the MD Codes section.

9. The method according to any of claims 1 or 2, characterized in that the method comprises visualizing the MDCodes.

10. The method according to any one of claims 1 or 2, comprising visualizing the MD Codes on a computer screen.

11. The method according to any one of claims 1, 2, 9 and 10, wherein said visualizing comprises overlaying any of said MD Codes set forth herein with an image of said object.

12. The method of claim 9, wherein the subject suffers from a cosmetic condition, defect or disease.

13. The method of claim 9, wherein the subject suffers from an aesthetic condition, defect, or disease.

14. The method of claim 9, wherein the subject suffers from a skin condition, defect or disease.

15. A system for implementing the method of any one of claims 1 or 2.

16. A method of treating a subject in need thereof, the method comprising:

providing an object;

treating the subject in need thereof by injecting a therapeutically effective amount of a pharmaceutical composition comprising a composition selected from the group consisting of: hyaluronic Acid (HA), HA-based fillers, HA derivatives, botulinum toxin type A (botulinum), fillers and combinations thereof,

wherein the treatment comprises injecting the patient at a site set forth in any one of figures 1-4 and figures 7-9 substantially as described in the MD DYNA Codes section.

17. The method of claim 16 wherein the HA derivative is selected from the group consisting of vitamins and HA oligomers.

18. The method of any one of claims 16-17, wherein the site is on the neck or face.

19. The method of any one of claims 16-17, wherein the site is under the facial muscles.

20. The method of any one of claims 16-17, wherein the site is on the facial muscle.

21. The method of any one of claims 16-17, wherein the site is within the facial muscle fibers.

22. A method according to any of claims 16-21, wherein the site is on the mandible.

23. The method of any one of claims 16-21, wherein the site is on the chin at a chin labrum angle.

24. The method of any one of claims 16-21, wherein the site is on a lower lip.

25. The method of any one of claims 16-21, wherein the location is on an empty space along the anterior jaw.

26. The method of any one of claims 16-25, wherein the subject is in need of aesthetic treatment.

27. The method of any one of claims 16-26, further comprising injecting a pharmaceutical composition comprising a composition selected from the group consisting of: hyaluronic Acid (HA), botulinum toxin, bulking agents and combinations thereof; and repeated at least once a year for at least five (5) years.

28. The method of any one of claims 16-27, wherein the pharmaceutical composition further comprises a composition selected from the group consisting of: collagen, antibiotics, anti-inflammatory agents, steroids, and combinations thereof.

29. The method of any one of claims 16-26, wherein the pharmaceutical ingredient is botulinum toxin type a.

30. The method of any one of claims 16-26, wherein the pharmaceutical composition is a long chain Hyaluronic Acid (HA) product.

31. The method of any one of claims 16-26, wherein the pharmaceutical composition comprises HA.

32. The method of any one of claims 16-26, wherein the pharmaceutical ingredient is deoxycholic acid.

33. The method of any one of claims 16-26, wherein the pharmaceutical ingredient comprises a vitamin.

34. The method of any one of claims 16-26, wherein the injection site is depicted in any one of figures 1-4 and 7-9 described in the MD dynamics section.

35. The method of claim 34 wherein the injection site is depicted in figure 1 in the MD dynamics section.

36. The method of claim 34 wherein the injection site is depicted in figure 2 in the MD dynamics section.

37. The method of claim 34 wherein the injection site is depicted in figure 3 in the MD dynamics section.

38. The method of claim 34 wherein the injection site is depicted in figure 4 in the MD dynamics section.

39. The method of claim 34 wherein the injection site is depicted in figure 7 in the MD dynamics section.

40. The method of claim 34 wherein the injection site is depicted in figure 8 in the MD dynamics section.

41. The method of claim 34 wherein the injection site is depicted in figure 9 in the MD dynamics section.

42. The method of any one of claims 16-40, further comprising visualizing the injection site.

43. The method of any one of claims 16-42, further comprising visualizing the injection site on a computer screen.

44. The method according to any one of claims 16-43, wherein the visualizing comprises overlaying any injection site described herein with an image of a subject in need thereof.

45. The method of any one of claims 16-44, wherein the subject suffers from an aesthetic disorder.

46. The method of any one of claims 16-44, wherein the subject suffers from a skin condition.

47. The method of any one of claims 16-46, wherein the method comprises injecting at least 0.5mL of a therapeutically effective amount of the pharmaceutical composition.

48. The method of any one of claims 16-47, comprising injecting said therapeutically effective amount of said pharmaceutical composition at a penetration depth of at least 2-6 mm.

49. The method of any one of claims 16-48, wherein the pharmaceutical composition is a cell body.

50. A system for implementing the method of any one of claims 1-48.

51. A syringe designed to carry out the method according to any one of claims 1 to 50.

52. A method of treating a subject in need thereof, the method comprising:

providing an object;

evaluating the subject according to the MD ASA map;

treating a subject in need thereof by injecting a therapeutically effective amount of a pharmaceutical composition comprising a component selected from the group consisting of: hyaluronic Acid (HA), botulinum toxin, bulking agent, and combinations thereof.

53. The method of claim 52, wherein evaluating the object comprises scoring an aesthetic rating.

54. The method of any one of claims 52-53, wherein evaluating the object comprises scoring an aesthetic rating substantially as shown in FIG. 3 as described in the MDASA section.

55. The method of any one of claims 52-54, wherein the treatment comprises injecting the subject at a site as described herein, in the drawings, or incorporated by reference.

56. The method of any one of claims 52-55, wherein the site is on the neck or face.

57. The method of any one of claims 52-57, wherein the subject is in need of aesthetic treatment.

58. The method of any one of claims 52-57, further comprising injecting a pharmaceutical composition comprising a composition selected from the group consisting of: hyaluronic Acid (HA), botulinum toxin, bulking agents and combinations thereof; and is

Injections are repeated at least once a year for at least five (5) years.

59. The method of any one of claims 52-58, wherein the pharmaceutical composition comprises a composition selected from the group consisting of: botulinum toxin type a (botulinum), collagen, hyaluronic acid, antibiotics, anti-inflammatory agents, steroids and combinations thereof.

60. The method of any one of claims 52-58, wherein the pharmaceutical composition is botulinum toxin type A.

61. The method of any one of claims 52-58, wherein the pharmaceutical composition is a long chain Hyaluronic Acid (HA) product.

62. The method of any one of claims 52-58, wherein the pharmaceutical composition comprises HA.

63. The method of any one of claims 52-58, wherein the pharmaceutical composition is deoxycholic acid.

64. The method of any one of claims 52-58, wherein the pharmaceutical ingredient comprises a vitamin.

65. The method of any one of claims 52-63, wherein the injection site is set forth in any one of the figures.

66. The method of any one of claims 52-64, further comprising visualizing the injection site.

67. The method of any one of claims 52-65, further comprising visualizing the injection site on a computer screen.

68. The method according to any one of claims 52-66, wherein said visualizing comprises overlaying any injection site described herein with an image of a subject in need thereof.

69. The method of any one of claims 52-67, wherein the subject suffers from an aesthetic disorder.

70. The method of any one of claims 52-68, wherein the subject suffers from a skin condition.

71. The method of any one of claims 52-68, wherein the method comprises injecting at least 0.5mL of a therapeutically effective amount of the pharmaceutical agent.

72. The method of any one of claims 52-68, comprising injecting said therapeutically effective amount of said pharmaceutical composition with a penetration depth of at least 2-6 mm.

73. The method of any one of claims 52-68, wherein the pharmaceutical composition is a cell body.

74. A system for implementing the method of any one of claims 52-71.

75. A syringe for carrying out the method according to any one of claims 52-71.

76. A method of treating a subject in need thereof:

providing a risk factor map;

identifying risk factors present in a subject in need thereof;

treating a subject in need thereof by injecting a pharmaceutical composition comprising a component selected from the group consisting of: hyaluronic Acid (HA), botulinum toxin, bulking agent, and combinations thereof.

77. The method of claim 76, wherein said risk factors comprise intrinsic factors selected from the group consisting of genetic factors.

78. The method of claim 77, wherein the risk factors comprise extrinsic factors selected from the group consisting of environmental factors.

79. The method of claim 78, wherein said risk factors include family health history.

80. The method of claim 78, wherein said risk factors include family aesthetic history.

81. The method of any one of claims 76-80, wherein the site is on the neck or face.

82. The method of any one of claims 76-81, wherein the subject is in need of aesthetic treatment.

83. The method of claim 76, wherein identifying the risk factor comprises overlapping a photograph of a subject in need thereof with a photograph of a parent of the same gender as the subject.

84. The method of claim 76, wherein identifying the risk factors comprises overlapping a photograph of a subject in need thereof with a photograph of a same gender child of the subject.

85. The method of any one of claims 76-84, further comprising injecting a pharmaceutical composition comprising a composition selected from the group consisting of: hyaluronic Acid (HA), botulinum toxin, bulking agents and combinations thereof; and is

The injection is repeated once a year or two years.

86. The method of any one of claims 76-85, wherein the subject in need thereof suffers from an aging disorder or disease.

87. The method of any one of claims 76-86, wherein the pharmaceutical composition comprises a composition selected from the group consisting of: botulinum toxin type a (botulinum), collagen, hyaluronic acid, antibiotics, anti-inflammatory agents, steroids and combinations thereof.

88. The method of claim 87, wherein the pharmaceutical composition is botulinum toxin type A.

89. The method of claim 87, wherein the pharmaceutical composition is a long chain Hyaluronic Acid (HA) product.

90. The method of claim 87, wherein the pharmaceutical composition comprises HA.

91. The method of claim 87, wherein the pharmaceutical composition is deoxycholic acid.

92. The method of any one of claims 76 to 91 wherein the injection site is substantially as described in any one of figures 6 to 8, 10 to 12, 26 to 29 and 40 described in the Next Human section.

93. The method of any one of claims 76 to 92, wherein the injection site is as described in any one of figures 6 to 8, 10 to 12, 26 to 29 and 40.

94. The method of any one of claims 76 to 93, comprising visualizing the injection site.

95. The method of any one of claims 76 to 94, comprising visualizing the injection site on a computer screen.

96. The method according to any one of claims 76-95, wherein said visualizing comprises overlaying any injection site described herein with an image of said subject.

97. The method of any one of claims 76-96, wherein the subject in need thereof suffers from an aesthetic disorder.

98. The method of any one of claims 76-97, wherein the subject in need thereof suffers from a skin disorder.

99. The method of any one of claims 76-98, wherein the method comprises injecting at least 0.5mL of a therapeutically effective amount of the pharmaceutical composition.

100. The method of any one of claims 76 to 99, wherein the method comprises injecting a therapeutically effective amount of the pharmaceutical composition at a penetration depth of at least 2-6mm or at the level of the bone.

101. The method of any one of claims 76-100, wherein the pharmaceutical composition is a cell body.

102. A system for implementing the method of any of claims 76-101.

103. A syringe designed to carry out the method according to any one of claims 76-101.

104. A method of treating a subject in need thereof, comprising:

diagnosing the subject to identify a disorder or disease;

selecting a treatment using MD Codes, MD Codes equation or MD Codes formula, wherein MD Codes indicates an injection site on the face or neck of the subject; and is

An effective amount of the pharmaceutical composition is injected at each injection site.

105. The method of claim 104, wherein the condition or disease is an aesthetic condition or disease.

106. The method as claimed in claim 104-105, wherein the pharmaceutical composition is a Hyaluronic Acid (HA) product.

107. The method of claim 106, wherein the HA concentration is 17.5mg/ml or 20 mg/ml.

108. The method of claim 104-107, wherein MD ASA is used to diagnose a subject.

109. The method as claimed in claim 104-108, wherein MD Codes is used.

110. The method as recited in claim 104-109, wherein the MD Codes equation is used.

111. The method as recited in claim 104-110, wherein the MD Codes formula is used.

112. The method as recited in claim 104-111, wherein the MD Codes are selected from the group consisting of: l Codes, FCodes, T Codes, Lp Codes, E Codes, M Codes, G Codes, C Codes, O Codes, Jw Codes, TtCodes, and N Codes.

113. The method of claim 112, wherein the L code is L1, L2, L3, L4, L5, L6, L7, L8; FCodes are F1, F2, F3; t Codes is T1, T2; e Codes are E1, E2, E3; g Codes is G1, G2; o Codes is O1, O2, O3; t Codes is Tt1, Tt2, Tt 3; ck Codes are Ck1, Ck 5; NL Codes is NL1, NL2, NL 3; the Lp code is Lp1, Lp2, Lp3, Lp4, Lp5, Lp6, Lp7 and Lp 8; m Codes is M1, M2, M3; c Codes are C1, C2, C3, C4, C5, C6; JwCodes is Jw1, Jw2, Jw3, Jw4, Jw 5; n Codes are N1, N2, N3, N4, N5.

114. The method of claim 104-113 wherein the disorder or disease or treatment thereof is characterized by emotional attributes.

115. The method of claim 114, for treating a subject having a ptosis appearance to achieve a less ptosis appearance, comprising:

the treatment method is selected using the MD Codes formula including one, two, three, four, five or six of the following MD Codes equations:

the equation Ck1+ Ck2+ Ck3+ Ck4

NL1+ NL2+ NL3

M1+ M2+ M3

The equations C1+ C2+ C6 and Jw1+ Jw2+ Jw3+ Jw4+ Jw5

Equation SK

The equation is SMF.

116. The method of claim 114, wherein treating a subject with a sad expression to achieve a less sad expression in the perioral area comprises:

the treatment method is selected using one, two, three, four, five or six of the following MD Codes equations:

the equation Ck1+ Ck2+ Ck3+ Ck4

NL1+ NL2+ NL3

The equation is Lp1+ Lp2+ Lp3+ Lp4+ Lp5+ Lp7+ Lp8

Lp6

The equations C1+ C2+ C6 and Jw1+ Jw2+ Jw3+ Jw4+ Jw5

SK; or

A method for treating a subject with a sad expression to obtain a less sad expression in the periocular region, comprising:

the treatment method is selected using one, two, three or four of the following MD Codes equations:

the equations E1+ E2+ E3 and T1+ T2

The equations Ck1+ Ck2+ Ck3 and Tt1+ Tt2+ Tt3

The equations G1+ G2 and O1+ O2+ O3

The equation SK.

117. The method of claim 114, for treating a subject having a tired appearance to achieve a less tired appearance, comprising:

the treatment method is selected using one, two, three, four or five of the following MD Codes equations:

equation: e1+ E2+ E3, T1+ T2

The equations Ck1+ Ck2+ Ck3, Tt1+ Tt2+ Tt3

The equation Ck1+ Ck2+ Ck3+ Ck4

The equations G1+ G2, O1+ O2+ O3

The equation SK.

118. The method of claim 114, for treating a subject with an angry expression to achieve a less angry expression, comprising:

the treatment method is selected using the MD Codes formula of one or both of the following MD Codes equations:

the equations G1+ G2, O1+ O2+ O3

The equations are Lp1+ Lp2+ Lp3+ Lp6, C1+ C2+ C3.

119. The method of claim 114, for treating a subject to obtain a slimmer appearance, comprising:

the treatment method is selected using the MD Codes formula of one or both of the following MD Codes equations:

the equations Ck1+ Ck2+ Ck4, C1+ C2+ C3+ C4+ C6

The equation is SMF.

120. The method of claim 114, for treating a subject to obtain a more negative/softer appearance, comprising:

the treatment method is selected using the MD Codes formula of one to ten of the following MD Codes equations:

f1+ F2+ F3

T1+ T2

The equations G1+ G2, O1+ O2+ O3

Equation E1+ E2+ E3

The equation Ck1+ Ck2+ Ck3

The equation Ck4+ Ck 5.

The equation is Lp1+ Lp2+ Lp3+ Lp4+ Lp5+ Lp6+ Lp7

Equation C1+ C2

Equation SK

The equation is SMF.

121. The method of claim 114, for treating a subject to obtain a more positive appearance, comprising:

the treatment method was selected using the MD Codes formula of one to six of the following MD Codes equations:

equation E1+ E2+ E3

Equation C1+ C2+ C5

The equation Jw1+ Jw2+ Jw3+ Jw4+ Jw5

Ck1+ Ck2

Ck4

The equation is SMF.

122. The method of claim 114, for treating a subject to obtain a younger appearance (upper and middle faces), comprising:

the treatment method was selected using the MD Codes formulas 1-14 in the following MD Codes equations:

f1+ F2+ F3

T1+ T2

Equation E1+ E2+ E3

The equations G1+ G2, O1+ O2+ O3

The equations Ck1+ Ck2+ Ck3, Tt1+ Tt2+ Tt3

The equation Ck1-Ck2+ Ck3+ Ck4

NL1+ NL2+ NL3

Equation Ck1+ Ck2+ Ck3+ Ck4+ Ck5 equation M1-M2+ M3

The equation is Lp1+ Lp2+ Lp3+ Lp4+ Lp5+ Lp6+ Lp7+ Lp8

The equation is Jw1-1-Jw2+ Jw3+ Jw4+ Jw5

The equation is C1+ C2+ C3+ C4+ C6

Equation SK

The equation is SMF.

123. The method of claim 114, wherein treating a subject to achieve a more appealing appearance for ethnicity-specificity comprises:

for caucasian subjects, treatment is selected using one, two or three of the following MD Codes equations:

the equation Ck1+ Ck2+ Ck3

The equation is Lp1+ Lp2+ Lp3+ Lp4+ Lp5+ Lp6+ Lp7

The equations G1+ G2, O1+ O2+ O3

For asian subjects, treatment was selected using the MD Codes formula of 1-6 of the following MD Codes equations:

f1+ F2+ F3

T1+ T2

The equations G1+ G2, O1+ O2+ O3

The equations Ck1+ Ck2+ Ck3, Tt1+ Tt2+ Tt3

Ck4

The equation is C1+ C2+ C3+ C4+ C6;

for indian or middle east subjects, treatment is selected using one, two, three or four of the following MD Codes equations:

the equations G1+ G2, O1+ O2+ O3

Equation E1+ E2+ E3

The equations Ck1+ Ck2+ Ck3, Tt1+ Tt2+ Tt3

The equation is Lp1+ Lp2+ Lp3+ Lp4+ Lp5+ Lp6+ Lp 7;

treatment for african descent, treatment is selected using one, two or three of the following MD Codes equations:

the equation Ck1+ Ck2+ Ck4

The equations Ck1+ Ck2+ Ck3, Tt1+ Tt2+ Tt3

The equation is C1+ C2+ C3+ C4+ C6.

124. A method of treating a subject in need thereof, the method comprising:

diagnosing the subject to identify a disorder or disease;

selecting a treatment using MD DYNA codes, wherein MD DYNA codes indicate an injection site on the face or neck of the subject; and

an effective amount of the pharmaceutical composition is injected at each injection site.

125. The method of claim 125, wherein the disease or condition is an aesthetic condition or disease.

126. The method of any one of claims 125-126, wherein the pharmaceutical composition is selected from the group consisting of: hyaluronic Acid (HA), HA-based fillers, HA derivatives, botulinum toxin type A (BoNT-A), fillers and combinations thereof.

127. The method as claimed in any one of claims 125-127, wherein MD ASA is used for diagnosing a subject.

128. The method as set forth in any one of claims 125-128, wherein the MDDYNA codes for periocular expression are selected from the group consisting of F, C, P and OOc.

129. The method of any one of claims 125-128, wherein the MDDYNA Codes used for perioral expression are selected from the group consisting of N, LAN, LLS, ZMi, Ami, DSN, 00, R, DAO, DLI, M and PL.

130. The method as set forth in any one of claims 125-130, wherein the injection is for chemical muscle modulation and the pharmaceutical composition is botulinum toxin type a.

131. The method of claim 131,

selecting MD DYNA Codes C + F to reduce the brow if the presence of glabellar and forehead lines is identified;

selecting MD DYNA Codes M + PL to reduce lines if the presence of chin and neck lines is identified;

if a decline in mouth angle is identified, then MD DYNA Codes DAO is selected to correct the decline.

132. The method as claimed in any one of claims 125-130, wherein the injection is for mechanical muscle modulation and the pharmaceutical composition is HA, HA-based bulking agent or HA derivative.

133. The method of claim 29,

selecting MD DYNA Codes M to reduce skin wrinkles if a pout is identified as skin wrinkling;

if a gum smile is identified, then select MD DYNA Codes select: DSN + LAN to correct gum smile and to lift the tip of the nose;

if there is an asymmetrical smile, then select MD DYNA Codes select: zmj + Zmi; to raise the mouth angle, particularly the left side.

134. The method of any one of claims 104-134 for diagnosing a condition or disease in a subject to be treated, the method comprising:

using MD ASA to identify the emotional profile of the disorder and determine the improvement desired; wherein the content of the first and second substances,

MD ASA takes into account the following factors: what the object requires, what the object expresses, what the object presents, and how the object feels;

MD ASA was evaluated for disease in the following order using the following aesthetic ratings: h1: full face, H2: one third of face and neck, H3: periocular and perioral analysis, H4: face unit, H5: facial subunits/distractions; wherein

H1 evaluating the perception of an object (emotional Properties)

H2 expression of evaluation object (symmetry and proportion)

H3 evaluation of expression (Activity)

H4 assessing the needs of a subject (Key facial region)

H5 evaluates the needs of the subject.

135. The method of claim 135, further comprising:

the treatment regions are prioritized by:

performing a questionnaire survey on the subject to evaluate each facial area at a level of love, like, tolerance, and disagreement;

providing a physician assessment to assess the ideal, good, acceptable, and unfavorable ratings for each facial region;

each face region is given a priority in rank.

136. The method as claimed in any one of claims 135-136, wherein MD ASA is used to assess the appearance of sagging, including assessing all facial regions, but prioritizing the following:

symptom 1: prolapsed cheek-anatomical unit: cheek

Symptom 2: deep nasolabial sulcus-anatomical unit: nasolabial sulcus

Symptom 3: lip line-dissection unit: corner pattern of mouth

Symptom 4: chin-anatomical unit: jaw line of lower jaw

Symptom 5: poor skin quality-anatomical unit: skin(s)

Symptom 6: submental fat-dissection unit: the submental region.

137. The method as claimed in any one of claims 135-136, wherein the MD AASA is used to evaluate the sad appearance of periocular regions, including evaluating all regions but giving priority to

Symptom 1: low eyebrow-dissecting unit: eyebrow, temple

Symptom 2: pouch/canthus move down-dissection unit: cheek, eyelid, lacrimal groove

Symptom 3: fringe-anatomical unit around the eye: eyebrow line, outer canthus/eye line

Symptom 4: poor skin quality-anatomical unit: the skin around the eyes.

138. The method as claimed in any one of claims 135-136, wherein the MDA ASA is present^TMFor assessing the sad appearance of periocular regions, including assessing all regions and prioritizing:

symptom 1: prolapsed cheek-anatomical unit: cheek

Symptom 2: deep nasolabial sulcus-anatomical unit: nasolabial sulcus

Symptom 3: lack of lip structure-anatomical unit: lip (lip)

Symptom 4: hypo-coma or oral commissure-anatomic unit: lip (lip)

Symptom 5: deep mouth fillet-dissection unit: lower jaw, mouth corner line

Symptom 6: poor skin quality-anatomical unit: the skin around the mouth.

139. Root of herbaceous plantThe method as set forth in any one of claims 135-136, wherein the MD AASA^TMFor assessing the appearance of tiredness, including assessing all areas and prioritizing:

symptom 1: low eyebrow-dissecting unit: eyebrow, temple

Symptom 2: pouch-dissecting unit: cheek, lacrimal groove

Symptom 3: prolapsed cheek-anatomical unit: cheek

Symptom 4: fringe-anatomical unit around the eye: eyebrow line, outer canthus/eye line

Symptom 5: poor skin quality-anatomical unit: skin.

140. The method as claimed in any one of claims 135-136, wherein MDA ASA is used to assess the expression of anger, including assessing all areas and prioritizing:

symptom 1: fringe-anatomical unit around the eye: eyebrow line, outer canthus/eye line

Symptom 2: lip and chin tension-dissection unit: lips, oral commissures, and chin.

141. The method as claimed in any one of claims 135-136, wherein MDA ASA is used to evaluate the facial shape, including evaluating all regions and prioritizing:

symptom 1: to modify the square, round or thick face type-anatomical unit: upper cheek, lower jaw

Symptom 2: submental fat-dissection unit: the submental region.

142. The method as claimed in any one of claims 135-136, wherein MDA ASA is used to assess the need for a more cloudy/softer appearance, including assessing all areas but giving priority to:

symptom 1: prominent forehead-anatomy unit: forehead (head)

Symptom 2: sunken temple-anatomy unit: temporal part

Symptom 3: fringe-anatomical unit around the eye: eyebrow line, outer canthus/eye line

Symptom 4: creating a higher eyebrow-dissecting unit: eyebrow

Symptom 5: to plump the upper cheek-anatomical unit: upper cheek

Symptom 6: establish sharpness/fullness-dissection unit in the lower cheek: lower cheek

Symptom 7: creating a complete and shaped lip-dissection unit: lip (lip)

Symptom 8: creating a triangular mandible-anatomical unit: lower jaw

Symptom 9: poor skin quality-anatomical unit: skin(s)

Symptom 10: submental fat-dissection unit: the submental region.

143. The method as claimed in any one of claims 135-136, wherein MDA ASA is used to evaluate the appearance of a need for more positive treatment, including evaluating all areas, but with priority:

symptom 1: creating a prominent above-eye-anatomical unit: eyebrow

Symptom 2: creating a mandible-anatomical unit: lower jaw

Symptom 3: creating a strong mandible-anatomical unit: lower jaw

Symptom 4: creating a strong cheek bone-anatomical unit: cheek

Symptom 5: shaping and face thinning-dissection unit: cheek

Symptom 6: submental fat-dissection unit: the submental region.

144. The method as claimed in any one of claims 135-136, wherein MDA ASA is used to assess the need for a more appealing appearance (upper and middle faces), including assessing all areas but giving priority to:

symptom 1: volume loss on forehead-anatomical unit: forehead (head)

Symptom 2: volume loss in the temporal part-anatomical unit: temporal part

Symptom 3: low eyebrow-dissecting unit: eyebrow

Symptom 4: fringe-anatomical unit around the eye: eyebrow line, outer canthus/eye line

Symptom 5: pouch-dissecting unit: cheek, lacrimal groove

Symptom 6: prolapsed cheek-anatomical unit: cheek

Symptom 7: nasolabial groove depth-anatomical unit: nasolabial sulcus

Symptom 8: compact and hollow cheek-anatomy unit: cheek

Symptom 9: lip line-dissection unit: corner pattern of mouth

Symptom 10: lip atrophy and wrinkles-anatomical unit: lip (lip)

Symptom 11: mandibular prolapse-anatomical unit: lower jaw

Symptom 12: mandibular aging-anatomical unit: lower jaw

Symptom 13: poor skin quality-anatomical unit: skin(s)

Symptom 14: submental fat-dissection unit: the submental region.

145. The method as set forth in any one of claims 135-136, wherein the MDA ASA is used to assess the need for a more attractive appearance with ethnicity, comprising:

assessing the need for a more attractive appearance of caucasian subjects, including assessing all areas, but with priority:

symptom 1: creating a high cheek bone-dissecting unit: cheek

Symptom 2: creating a complete and shaped lip-dissection unit: lip (lip)

Symptom 3: fringe-anatomical unit around the eye: eyebrow lines, outer canthus/eye lines;

assessing the need for a more attractive appearance of asian subjects, including assessing all areas, but with priority:

symptom 1: forehead/robust forehead-anatomy unit: forehead (head)

Symptom 2: sunken temple-anatomy unit: temporal part

Symptom 3: fringe-anatomical unit around the eye: eyebrow line, outer canthus/eye line

Symptom 4: enhanced eye shape-anatomical unit: cheek, lacrimal groove

Symptom 5: face thinning-anatomical unit: lower cheek

Symptom 6: enhancing the mandible-anatomical unit: a lower jaw;

the need for a more attractive appearance of indian or middle east subjects, including assessment of all areas, but with priority:

symptom 1: fringe-anatomical unit around the eye: eyebrow line, outer canthus/eye line

Symptom 2: low eyebrow-dissecting unit: eyebrow

Marker 3: prominent lacrimal groove-anatomical unit: cheek, lacrimal groove

Symptom 4: lip sizing unclear/collapse-anatomical unit: lips;

the need for a more attractive appearance of indian or african descendant subjects includes assessing all regions, but giving priority to:

symptom 1: enhanced mid-face shape-anatomical unit: cheek

Symptom 2: enhanced eye shape-anatomical unit: cheek, lacrimal groove

Symptom 3: enhancing the mandible-anatomical unit: and a lower jaw.